nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Masoprocol—IGF1R—sarcoma	0.0195	1	CrCbGaD
L-DOPA—PSIP1—myometrium—sarcoma	0.0148	0.052	CbGeAlD
L-DOPA—PSIP1—embryo—sarcoma	0.0142	0.05	CbGeAlD
L-DOPA—SLC7A8—mammary gland—sarcoma	0.0137	0.0483	CbGeAlD
L-DOPA—PSIP1—seminal vesicle—sarcoma	0.0134	0.047	CbGeAlD
L-DOPA—PSIP1—hematopoietic system—sarcoma	0.0127	0.0447	CbGeAlD
L-DOPA—PSIP1—Teniposide—Etoposide—sarcoma	0.0111	0.372	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—sarcoma	0.0111	0.372	CbGdCrCtD
L-DOPA—SLC7A5—mammary gland—sarcoma	0.0106	0.0374	CbGeAlD
L-DOPA—PSIP1—uterus—sarcoma	0.00959	0.0337	CbGeAlD
L-DOPA—PSIP1—lymphoid tissue—sarcoma	0.00893	0.0314	CbGeAlD
L-DOPA—PSIP1—bone marrow—sarcoma	0.00813	0.0286	CbGeAlD
L-DOPA—DDC—embryo—sarcoma	0.00811	0.0285	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vincristine—sarcoma	0.00763	0.256	CbGdCrCtD
L-DOPA—SLC7A5—myometrium—sarcoma	0.00755	0.0266	CbGeAlD
L-DOPA—SLC7A8—skin of body—sarcoma	0.00727	0.0256	CbGeAlD
L-DOPA—DRD5—hematopoietic system—sarcoma	0.00696	0.0245	CbGeAlD
L-DOPA—PSIP1—testis—sarcoma	0.00695	0.0245	CbGeAlD
L-DOPA—SLC7A5—seminal vesicle—sarcoma	0.00682	0.024	CbGeAlD
L-DOPA—PSIP1—liver—sarcoma	0.00657	0.0231	CbGeAlD
L-DOPA—SLC7A5—hematopoietic system—sarcoma	0.00648	0.0228	CbGeAlD
L-DOPA—SLC7A5—connective tissue—sarcoma	0.00624	0.022	CbGeAlD
L-DOPA—DRD4—testis—sarcoma	0.00579	0.0204	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—sarcoma	0.00571	0.0201	CbGeAlD
L-DOPA—SLC7A5—skin of body—sarcoma	0.00563	0.0198	CbGeAlD
L-DOPA—SLC7A8—tendon—sarcoma	0.00553	0.0195	CbGeAlD
L-DOPA—PSIP1—lymph node—sarcoma	0.00504	0.0177	CbGeAlD
L-DOPA—SLC16A10—hematopoietic system—sarcoma	0.00496	0.0175	CbGeAlD
L-DOPA—SLC7A5—cardiac atrium—sarcoma	0.00492	0.0173	CbGeAlD
L-DOPA—DRD5—lymphoid tissue—sarcoma	0.0049	0.0172	CbGeAlD
L-DOPA—SLC7A5—uterus—sarcoma	0.0049	0.0172	CbGeAlD
L-DOPA—SLC7A8—testis—sarcoma	0.00458	0.0161	CbGeAlD
L-DOPA—SLC7A5—lymphoid tissue—sarcoma	0.00456	0.0161	CbGeAlD
L-DOPA—SLC7A8—liver—sarcoma	0.00433	0.0152	CbGeAlD
L-DOPA—SLC7A5—tendon—sarcoma	0.00429	0.0151	CbGeAlD
L-DOPA—SLC7A5—bone marrow—sarcoma	0.00415	0.0146	CbGeAlD
L-DOPA—DDC—testis—sarcoma	0.00397	0.014	CbGeAlD
L-DOPA—DDC—liver—sarcoma	0.00375	0.0132	CbGeAlD
L-DOPA—SLC7A5—testis—sarcoma	0.00355	0.0125	CbGeAlD
L-DOPA—SLC16A10—lymphoid tissue—sarcoma	0.00349	0.0123	CbGeAlD
L-DOPA—SLC7A5—liver—sarcoma	0.00336	0.0118	CbGeAlD
L-DOPA—SLC7A8—lymph node—sarcoma	0.00332	0.0117	CbGeAlD
L-DOPA—SLC16A10—tendon—sarcoma	0.00328	0.0116	CbGeAlD
L-DOPA—DDC—lymph node—sarcoma	0.00287	0.0101	CbGeAlD
L-DOPA—SLC15A1—liver—sarcoma	0.00279	0.00981	CbGeAlD
L-DOPA—SLC16A10—testis—sarcoma	0.00272	0.00957	CbGeAlD
L-DOPA—SLC7A5—lymph node—sarcoma	0.00257	0.00906	CbGeAlD
L-DOPA—SLC16A10—liver—sarcoma	0.00257	0.00905	CbGeAlD
L-DOPA—SLC16A10—lymph node—sarcoma	0.00197	0.00694	CbGeAlD
L-DOPA—CYP2D6—hematopoietic system—sarcoma	0.00189	0.00664	CbGeAlD
L-DOPA—DRD2—testis—sarcoma	0.00172	0.00606	CbGeAlD
L-DOPA—Paraesthesia—Vincristine—sarcoma	0.00119	0.002	CcSEcCtD
L-DOPA—Urticaria—Thiotepa—sarcoma	0.00119	0.002	CcSEcCtD
L-DOPA—Malaise—Etoposide—sarcoma	0.00119	0.002	CcSEcCtD
L-DOPA—Dermatitis bullous—Doxorubicin—sarcoma	0.00119	0.00199	CcSEcCtD
L-DOPA—Abdominal pain—Thiotepa—sarcoma	0.00119	0.00199	CcSEcCtD
L-DOPA—Leukopenia—Etoposide—sarcoma	0.00118	0.00198	CcSEcCtD
L-DOPA—Purpura—Doxorubicin—sarcoma	0.00118	0.00198	CcSEcCtD
L-DOPA—Abdominal pain—Dactinomycin—sarcoma	0.00118	0.00197	CcSEcCtD
L-DOPA—Paraesthesia—Mitoxantrone—sarcoma	0.00116	0.00195	CcSEcCtD
L-DOPA—Loss of consciousness—Etoposide—sarcoma	0.00116	0.00195	CcSEcCtD
L-DOPA—Decreased appetite—Vincristine—sarcoma	0.00116	0.00194	CcSEcCtD
L-DOPA—Ataxia—Epirubicin—sarcoma	0.00116	0.00194	CcSEcCtD
L-DOPA—Dyspnoea—Mitoxantrone—sarcoma	0.00116	0.00194	CcSEcCtD
L-DOPA—Cough—Etoposide—sarcoma	0.00115	0.00193	CcSEcCtD
L-DOPA—Somnolence—Mitoxantrone—sarcoma	0.00115	0.00193	CcSEcCtD
L-DOPA—Blood creatinine increased—Epirubicin—sarcoma	0.00115	0.00193	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Vincristine—sarcoma	0.00115	0.00192	CcSEcCtD
L-DOPA—Fatigue—Vincristine—sarcoma	0.00115	0.00192	CcSEcCtD
L-DOPA—Convulsion—Etoposide—sarcoma	0.00114	0.00192	CcSEcCtD
L-DOPA—Dyspepsia—Mitoxantrone—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Hypertension—Etoposide—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Pain—Vincristine—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Constipation—Vincristine—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—sarcoma	0.00114	0.00191	CcSEcCtD
L-DOPA—Decreased appetite—Mitoxantrone—sarcoma	0.00113	0.00189	CcSEcCtD
L-DOPA—Chest pain—Etoposide—sarcoma	0.00112	0.00188	CcSEcCtD
L-DOPA—Orthostatic hypotension—Epirubicin—sarcoma	0.00112	0.00188	CcSEcCtD
L-DOPA—Fatigue—Mitoxantrone—sarcoma	0.00112	0.00187	CcSEcCtD
L-DOPA—Discomfort—Etoposide—sarcoma	0.00111	0.00186	CcSEcCtD
L-DOPA—Pain—Mitoxantrone—sarcoma	0.00111	0.00186	CcSEcCtD
L-DOPA—Constipation—Mitoxantrone—sarcoma	0.00111	0.00186	CcSEcCtD
L-DOPA—Hypersensitivity—Thiotepa—sarcoma	0.00111	0.00185	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—sarcoma	0.0011	0.00184	CcSEcCtD
L-DOPA—Hypersensitivity—Dactinomycin—sarcoma	0.0011	0.00184	CcSEcCtD
L-DOPA—Gastrointestinal pain—Vincristine—sarcoma	0.00109	0.00182	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—sarcoma	0.00109	0.00182	CcSEcCtD
L-DOPA—Confusional state—Etoposide—sarcoma	0.00109	0.00182	CcSEcCtD
L-DOPA—Asthenia—Thiotepa—sarcoma	0.00108	0.0018	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—sarcoma	0.00107	0.00179	CcSEcCtD
L-DOPA—Asthenia—Dactinomycin—sarcoma	0.00107	0.00179	CcSEcCtD
L-DOPA—Feeling abnormal—Mitoxantrone—sarcoma	0.00107	0.00179	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—sarcoma	0.00107	0.00179	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—sarcoma	0.00106	0.00178	CcSEcCtD
L-DOPA—Pruritus—Thiotepa—sarcoma	0.00106	0.00178	CcSEcCtD
L-DOPA—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00106	0.00178	CcSEcCtD
L-DOPA—Thrombocytopenia—Etoposide—sarcoma	0.00106	0.00177	CcSEcCtD
L-DOPA—Abdominal pain—Vincristine—sarcoma	0.00105	0.00176	CcSEcCtD
L-DOPA—Hyperhidrosis—Etoposide—sarcoma	0.00104	0.00175	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—sarcoma	0.00104	0.00174	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—sarcoma	0.00103	0.00173	CcSEcCtD
L-DOPA—CYP2D6—testis—sarcoma	0.00103	0.00364	CbGeAlD
L-DOPA—Urticaria—Mitoxantrone—sarcoma	0.00103	0.00172	CcSEcCtD
L-DOPA—Anorexia—Etoposide—sarcoma	0.00103	0.00172	CcSEcCtD
L-DOPA—Diarrhoea—Thiotepa—sarcoma	0.00103	0.00172	CcSEcCtD
L-DOPA—Abdominal pain—Mitoxantrone—sarcoma	0.00102	0.00172	CcSEcCtD
L-DOPA—Diarrhoea—Dactinomycin—sarcoma	0.00102	0.00171	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—sarcoma	0.00102	0.0017	CcSEcCtD
L-DOPA—Hypotension—Etoposide—sarcoma	0.00101	0.00169	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—sarcoma	0.00101	0.00169	CcSEcCtD
L-DOPA—Dizziness—Thiotepa—sarcoma	0.000992	0.00166	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—sarcoma	0.000987	0.00165	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—sarcoma	0.000983	0.00165	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—sarcoma	0.000981	0.00164	CcSEcCtD
L-DOPA—Hypersensitivity—Vincristine—sarcoma	0.00098	0.00164	CcSEcCtD
L-DOPA—CYP2D6—liver—sarcoma	0.000978	0.00344	CbGeAlD
L-DOPA—Paraesthesia—Etoposide—sarcoma	0.000968	0.00162	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—sarcoma	0.000967	0.00162	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—sarcoma	0.000961	0.00161	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—sarcoma	0.000961	0.00161	CcSEcCtD
L-DOPA—Somnolence—Etoposide—sarcoma	0.000958	0.00161	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—sarcoma	0.000958	0.0016	CcSEcCtD
L-DOPA—Hypersensitivity—Mitoxantrone—sarcoma	0.000955	0.0016	CcSEcCtD
L-DOPA—Asthenia—Vincristine—sarcoma	0.000955	0.0016	CcSEcCtD
L-DOPA—Vomiting—Thiotepa—sarcoma	0.000954	0.0016	CcSEcCtD
L-DOPA—Vomiting—Dactinomycin—sarcoma	0.000947	0.00159	CcSEcCtD
L-DOPA—Rash—Thiotepa—sarcoma	0.000946	0.00159	CcSEcCtD
L-DOPA—Dermatitis—Thiotepa—sarcoma	0.000945	0.00158	CcSEcCtD
L-DOPA—Headache—Thiotepa—sarcoma	0.00094	0.00158	CcSEcCtD
L-DOPA—Rash—Dactinomycin—sarcoma	0.000939	0.00157	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—sarcoma	0.000937	0.00157	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Etoposide—sarcoma	0.000931	0.00156	CcSEcCtD
L-DOPA—Asthenia—Mitoxantrone—sarcoma	0.00093	0.00156	CcSEcCtD
L-DOPA—Fatigue—Etoposide—sarcoma	0.000929	0.00156	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—sarcoma	0.000929	0.00156	CcSEcCtD
L-DOPA—Pain—Etoposide—sarcoma	0.000922	0.00154	CcSEcCtD
L-DOPA—Constipation—Etoposide—sarcoma	0.000922	0.00154	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—sarcoma	0.000921	0.00154	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000914	0.00153	CcSEcCtD
L-DOPA—Diarrhoea—Vincristine—sarcoma	0.00091	0.00153	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—sarcoma	0.000908	0.00152	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—sarcoma	0.000895	0.0015	CcSEcCtD
L-DOPA—Nausea—Thiotepa—sarcoma	0.000891	0.00149	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—sarcoma	0.000889	0.00149	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—sarcoma	0.000888	0.00149	CcSEcCtD
L-DOPA—Diarrhoea—Mitoxantrone—sarcoma	0.000887	0.00149	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—sarcoma	0.000885	0.00148	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—sarcoma	0.000884	0.00148	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—sarcoma	0.000881	0.00148	CcSEcCtD
L-DOPA—Dizziness—Vincristine—sarcoma	0.00088	0.00147	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—sarcoma	0.000859	0.00144	CcSEcCtD
L-DOPA—Urticaria—Etoposide—sarcoma	0.000856	0.00143	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—sarcoma	0.000855	0.00143	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—sarcoma	0.000853	0.00143	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—sarcoma	0.000852	0.00143	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—sarcoma	0.000852	0.00143	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—sarcoma	0.00085	0.00143	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—sarcoma	0.000846	0.00142	CcSEcCtD
L-DOPA—Vomiting—Vincristine—sarcoma	0.000846	0.00142	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—sarcoma	0.00084	0.00141	CcSEcCtD
L-DOPA—Rash—Vincristine—sarcoma	0.000839	0.00141	CcSEcCtD
L-DOPA—Dermatitis—Vincristine—sarcoma	0.000838	0.0014	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—sarcoma	0.000834	0.0014	CcSEcCtD
L-DOPA—Headache—Vincristine—sarcoma	0.000834	0.0014	CcSEcCtD
L-DOPA—Vomiting—Mitoxantrone—sarcoma	0.000824	0.00138	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—sarcoma	0.000818	0.00137	CcSEcCtD
L-DOPA—Rash—Mitoxantrone—sarcoma	0.000817	0.00137	CcSEcCtD
L-DOPA—Dermatitis—Mitoxantrone—sarcoma	0.000816	0.00137	CcSEcCtD
L-DOPA—Headache—Mitoxantrone—sarcoma	0.000812	0.00136	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—sarcoma	0.000794	0.00133	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—sarcoma	0.000791	0.00133	CcSEcCtD
L-DOPA—Nausea—Vincristine—sarcoma	0.00079	0.00132	CcSEcCtD
L-DOPA—Flushing—Epirubicin—sarcoma	0.000789	0.00132	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—sarcoma	0.000789	0.00132	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—sarcoma	0.000787	0.00132	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—sarcoma	0.000783	0.00131	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—sarcoma	0.000777	0.0013	CcSEcCtD
L-DOPA—Asthenia—Etoposide—sarcoma	0.000773	0.0013	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—sarcoma	0.000771	0.00129	CcSEcCtD
L-DOPA—Nausea—Mitoxantrone—sarcoma	0.00077	0.00129	CcSEcCtD
L-DOPA—Pruritus—Etoposide—sarcoma	0.000763	0.00128	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—sarcoma	0.00076	0.00127	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—sarcoma	0.000751	0.00126	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—sarcoma	0.000745	0.00125	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—sarcoma	0.000737	0.00124	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—sarcoma	0.00073	0.00122	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—sarcoma	0.000729	0.00122	CcSEcCtD
L-DOPA—Tension—Epirubicin—sarcoma	0.000726	0.00122	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—sarcoma	0.000725	0.00121	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—sarcoma	0.000719	0.0012	CcSEcCtD
L-DOPA—Back pain—Epirubicin—sarcoma	0.000716	0.0012	CcSEcCtD
L-DOPA—Dizziness—Etoposide—sarcoma	0.000713	0.00119	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—sarcoma	0.000712	0.00119	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—sarcoma	0.000703	0.00118	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—sarcoma	0.000698	0.00117	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—sarcoma	0.000695	0.00117	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—sarcoma	0.000689	0.00116	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—sarcoma	0.000687	0.00115	CcSEcCtD
L-DOPA—Vomiting—Etoposide—sarcoma	0.000685	0.00115	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—sarcoma	0.000684	0.00115	CcSEcCtD
L-DOPA—Agitation—Epirubicin—sarcoma	0.00068	0.00114	CcSEcCtD
L-DOPA—Rash—Etoposide—sarcoma	0.00068	0.00114	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—sarcoma	0.000679	0.00114	CcSEcCtD
L-DOPA—Headache—Etoposide—sarcoma	0.000675	0.00113	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—sarcoma	0.000675	0.00113	CcSEcCtD
L-DOPA—Tension—Doxorubicin—sarcoma	0.000672	0.00113	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—sarcoma	0.000671	0.00112	CcSEcCtD
L-DOPA—Malaise—Epirubicin—sarcoma	0.000668	0.00112	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—sarcoma	0.000665	0.00111	CcSEcCtD
L-DOPA—Syncope—Epirubicin—sarcoma	0.000664	0.00111	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—sarcoma	0.000663	0.00111	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—sarcoma	0.000663	0.00111	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—sarcoma	0.000659	0.0011	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—sarcoma	0.000654	0.0011	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—sarcoma	0.000651	0.00109	CcSEcCtD
L-DOPA—Cough—Epirubicin—sarcoma	0.000646	0.00108	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—sarcoma	0.000646	0.00108	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—sarcoma	0.000641	0.00107	CcSEcCtD
L-DOPA—Nausea—Etoposide—sarcoma	0.00064	0.00107	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—sarcoma	0.000639	0.00107	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—sarcoma	0.000636	0.00106	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—sarcoma	0.000633	0.00106	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—sarcoma	0.00063	0.00106	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—sarcoma	0.000629	0.00105	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—sarcoma	0.000628	0.00105	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—sarcoma	0.000623	0.00104	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—sarcoma	0.000618	0.00104	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—sarcoma	0.000616	0.00103	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—sarcoma	0.000614	0.00103	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—sarcoma	0.000613	0.00103	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—sarcoma	0.000609	0.00102	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—sarcoma	0.000605	0.00101	CcSEcCtD
L-DOPA—Oedema—Epirubicin—sarcoma	0.000604	0.00101	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—sarcoma	0.000602	0.00101	CcSEcCtD
L-DOPA—Cough—Doxorubicin—sarcoma	0.000598	0.001	CcSEcCtD
L-DOPA—Shock—Epirubicin—sarcoma	0.000594	0.000996	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—sarcoma	0.000593	0.000994	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—sarcoma	0.000592	0.000991	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—sarcoma	0.000591	0.000991	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—sarcoma	0.000584	0.000979	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—sarcoma	0.000583	0.000977	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—sarcoma	0.000581	0.000974	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—sarcoma	0.000576	0.000965	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—sarcoma	0.000576	0.000965	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—sarcoma	0.00057	0.000956	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—sarcoma	0.000565	0.000946	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—sarcoma	0.000564	0.000945	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—sarcoma	0.000559	0.000937	CcSEcCtD
L-DOPA—Shock—Doxorubicin—sarcoma	0.00055	0.000922	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—sarcoma	0.000547	0.000917	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—sarcoma	0.000546	0.000916	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—sarcoma	0.000543	0.000909	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—sarcoma	0.00054	0.000906	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—sarcoma	0.000539	0.000903	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—sarcoma	0.000537	0.0009	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—sarcoma	0.000533	0.000893	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—sarcoma	0.000532	0.000891	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—sarcoma	0.000525	0.00088	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—sarcoma	0.000522	0.000875	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—sarcoma	0.000522	0.000874	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—sarcoma	0.000521	0.000873	CcSEcCtD
L-DOPA—Pain—Epirubicin—sarcoma	0.000517	0.000866	CcSEcCtD
L-DOPA—Constipation—Epirubicin—sarcoma	0.000517	0.000866	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—sarcoma	0.000506	0.000847	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—sarcoma	0.000502	0.000841	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—sarcoma	0.000498	0.000835	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—sarcoma	0.000498	0.000834	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—sarcoma	0.000497	0.000833	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—sarcoma	0.000494	0.000828	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—sarcoma	0.000492	0.000825	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—sarcoma	0.000486	0.000814	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000483	0.000809	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—sarcoma	0.000482	0.000808	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—sarcoma	0.00048	0.000804	CcSEcCtD
L-DOPA—Pain—Doxorubicin—sarcoma	0.000478	0.000801	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—sarcoma	0.000478	0.000801	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—sarcoma	0.000478	0.0008	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—sarcoma	0.000461	0.000772	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—sarcoma	0.000457	0.000766	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—sarcoma	0.000445	0.000746	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—sarcoma	0.000444	0.000744	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—sarcoma	0.000442	0.000741	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—sarcoma	0.000433	0.000726	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—sarcoma	0.000427	0.000716	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—sarcoma	0.000413	0.000693	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—sarcoma	0.000412	0.00069	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—PLCG1—sarcoma	0.000405	0.0058	CbGpPWpGaD
L-DOPA—Asthenia—Doxorubicin—sarcoma	0.000401	0.000672	CcSEcCtD
L-DOPA—SLC7A8—Cell surface interactions at the vascular wall—HRAS—sarcoma	0.0004	0.00573	CbGpPWpGaD
L-DOPA—Dizziness—Epirubicin—sarcoma	0.0004	0.000669	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—sarcoma	0.000396	0.000663	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—sarcoma	0.000384	0.000644	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—sarcoma	0.000382	0.000641	CcSEcCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000382	0.00548	CbGpPWpGaD
L-DOPA—Rash—Epirubicin—sarcoma	0.000381	0.000638	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—sarcoma	0.000381	0.000638	CcSEcCtD
L-DOPA—Headache—Epirubicin—sarcoma	0.000378	0.000634	CcSEcCtD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000375	0.00537	CbGpPWpGaD
L-DOPA—Dizziness—Doxorubicin—sarcoma	0.00037	0.000619	CcSEcCtD
L-DOPA—Nausea—Epirubicin—sarcoma	0.000359	0.000601	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—sarcoma	0.000355	0.000596	CcSEcCtD
L-DOPA—Rash—Doxorubicin—sarcoma	0.000352	0.000591	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—sarcoma	0.000352	0.00059	CcSEcCtD
L-DOPA—Headache—Doxorubicin—sarcoma	0.00035	0.000587	CcSEcCtD
L-DOPA—SLC7A5—Cell surface interactions at the vascular wall—HRAS—sarcoma	0.000349	0.005	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PLCG1—sarcoma	0.000344	0.00494	CbGpPWpGaD
L-DOPA—Nausea—Doxorubicin—sarcoma	0.000332	0.000556	CcSEcCtD
L-DOPA—PSIP1—Disease—CXCR4—sarcoma	0.000331	0.00474	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000321	0.0046	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—CREB1—sarcoma	0.000312	0.00447	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—CXCR4—sarcoma	0.000298	0.00427	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000276	0.00397	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—JUN—sarcoma	0.000275	0.00394	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000273	0.00391	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CXCR4—sarcoma	0.000265	0.0038	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000249	0.00357	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000246	0.00352	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCR4—sarcoma	0.000244	0.00351	CbGpPWpGaD
L-DOPA—PSIP1—Disease—FOXO1—sarcoma	0.000244	0.0035	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PDGFRB—sarcoma	0.000244	0.0035	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PDGFRA—sarcoma	0.00024	0.00344	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.00024	0.00344	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000237	0.0034	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—JUN—sarcoma	0.000224	0.00322	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000213	0.00306	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.00021	0.00302	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCR4—sarcoma	0.000202	0.0029	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000188	0.0027	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KIT—sarcoma	0.000186	0.00267	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—CREB1—sarcoma	0.000181	0.00259	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCR4—sarcoma	0.00018	0.00259	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CREB1—sarcoma	0.000177	0.00254	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—IL2—sarcoma	0.000176	0.00253	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—CREB1—sarcoma	0.000163	0.00233	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCR4—sarcoma	0.000162	0.00233	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000161	0.00231	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—CREB1—sarcoma	0.000161	0.0023	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCR4—sarcoma	0.00016	0.0023	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—SRC—sarcoma	0.000154	0.00221	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—IL2—sarcoma	0.000154	0.00221	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—VEGFA—sarcoma	0.00015	0.00215	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—NRAS—sarcoma	0.000148	0.00212	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—sarcoma	0.000148	0.00212	CbGpPWpGaD
L-DOPA—PSIP1—Disease—MDM2—sarcoma	0.000147	0.0021	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ENO2—sarcoma	0.000138	0.00198	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCR4—sarcoma	0.000138	0.00198	CbGpPWpGaD
L-DOPA—DDC—Metabolism—HBA1—sarcoma	0.000137	0.00197	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—SRC—sarcoma	0.000134	0.00193	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—VEGFA—sarcoma	0.000131	0.00188	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—JUN—sarcoma	0.00013	0.00187	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—NRAS—sarcoma	0.000129	0.00185	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—KRAS—sarcoma	0.000127	0.00183	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CTNNB1—sarcoma	0.000126	0.00181	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCR4—sarcoma	0.000125	0.0018	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—CREB1—sarcoma	0.000123	0.00176	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCR4—sarcoma	0.000123	0.00176	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PLCG1—sarcoma	0.000117	0.00168	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—JUN—sarcoma	0.000117	0.00168	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TLE1—sarcoma	0.000116	0.00167	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—JUN—sarcoma	0.000116	0.00166	CbGpPWpGaD
L-DOPA—PSIP1—Disease—SRC—sarcoma	0.000114	0.00164	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—sarcoma	0.000113	0.00163	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—KRAS—sarcoma	0.000111	0.0016	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NRAS—sarcoma	0.00011	0.00158	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—HRAS—sarcoma	0.000108	0.00155	CbGpPWpGaD
L-DOPA—PSIP1—Disease—MYC—sarcoma	0.000102	0.00147	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCR4—sarcoma	0.000102	0.00146	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EGFR—sarcoma	0.0001	0.00144	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—sarcoma	9.89e-05	0.00142	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFC—sarcoma	9.81e-05	0.00141	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KRAS—sarcoma	9.46e-05	0.00136	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HRAS—sarcoma	9.46e-05	0.00136	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCR4—sarcoma	9.26e-05	0.00133	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCR4—sarcoma	9.18e-05	0.00132	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCR4—sarcoma	9.05e-05	0.0013	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—JUN—sarcoma	8.84e-05	0.00127	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TLE1—sarcoma	8.58e-05	0.00123	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—sarcoma	8.58e-05	0.00123	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCR4—sarcoma	8.33e-05	0.0012	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCR4—sarcoma	8.22e-05	0.00118	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HRAS—sarcoma	8.04e-05	0.00115	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FLT1—sarcoma	7.84e-05	0.00113	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TLE1—sarcoma	7.73e-05	0.00111	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—sarcoma	7.73e-05	0.00111	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PLCG1—sarcoma	7.71e-05	0.00111	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TLE1—sarcoma	7.62e-05	0.00109	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—sarcoma	7.62e-05	0.00109	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCR4—sarcoma	7.41e-05	0.00106	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ATF1—sarcoma	7.33e-05	0.00105	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFC—sarcoma	7.24e-05	0.00104	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCR4—sarcoma	6.93e-05	0.000994	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CREB1—sarcoma	6.72e-05	0.000964	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFC—sarcoma	6.52e-05	0.000935	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFC—sarcoma	6.43e-05	0.000923	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCR4—sarcoma	6.29e-05	0.000902	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TLE1—sarcoma	5.83e-05	0.000837	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—sarcoma	5.83e-05	0.000837	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FLT1—sarcoma	5.79e-05	0.000831	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1R—sarcoma	5.75e-05	0.000825	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PLCG1—sarcoma	5.69e-05	0.000816	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FOXO1—sarcoma	5.47e-05	0.000785	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2—sarcoma	5.47e-05	0.000784	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCR4—sarcoma	5.47e-05	0.000784	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PDGFRB—sarcoma	5.46e-05	0.000783	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ATF1—sarcoma	5.41e-05	0.000776	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PDGFRA—sarcoma	5.38e-05	0.000771	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FLT1—sarcoma	5.21e-05	0.000748	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FLT1—sarcoma	5.14e-05	0.000738	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLCG1—sarcoma	5.12e-05	0.000735	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLCG1—sarcoma	5.06e-05	0.000725	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2—sarcoma	4.97e-05	0.000712	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CREB1—sarcoma	4.96e-05	0.000711	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFC—sarcoma	4.92e-05	0.000706	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCR4—sarcoma	4.92e-05	0.000706	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ATF1—sarcoma	4.87e-05	0.000698	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCR4—sarcoma	4.86e-05	0.000697	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ATF1—sarcoma	4.8e-05	0.000689	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KDR—sarcoma	4.53e-05	0.000649	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CREB1—sarcoma	4.46e-05	0.00064	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CREB1—sarcoma	4.4e-05	0.000632	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1R—sarcoma	4.24e-05	0.000609	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KIT—sarcoma	4.17e-05	0.000598	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—NRAS—sarcoma	4.17e-05	0.000598	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FOXO1—sarcoma	4.04e-05	0.000579	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—sarcoma	4.04e-05	0.000579	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDGFRB—sarcoma	4.03e-05	0.000578	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CREB1—sarcoma	3.97e-05	0.000569	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDGFRA—sarcoma	3.97e-05	0.000569	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FLT1—sarcoma	3.94e-05	0.000564	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLCG1—sarcoma	3.87e-05	0.000555	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1R—sarcoma	3.82e-05	0.000548	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—sarcoma	3.8e-05	0.000545	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1R—sarcoma	3.77e-05	0.000541	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCR4—sarcoma	3.72e-05	0.000533	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ATF1—sarcoma	3.67e-05	0.000527	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—sarcoma	3.67e-05	0.000526	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FOXO1—sarcoma	3.64e-05	0.000521	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—sarcoma	3.63e-05	0.000521	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDGFRB—sarcoma	3.63e-05	0.000521	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—sarcoma	3.59e-05	0.000515	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FOXO1—sarcoma	3.59e-05	0.000515	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—sarcoma	3.59e-05	0.000514	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDGFRB—sarcoma	3.58e-05	0.000514	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDGFRA—sarcoma	3.57e-05	0.000512	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDGFRA—sarcoma	3.52e-05	0.000506	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CREB1—sarcoma	3.37e-05	0.000483	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—sarcoma	3.34e-05	0.000479	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—sarcoma	3.3e-05	0.000473	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MDM2—sarcoma	3.28e-05	0.000471	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—sarcoma	3.26e-05	0.000467	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—sarcoma	3.18e-05	0.000456	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HBA1—sarcoma	3.16e-05	0.000453	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KIT—sarcoma	3.08e-05	0.000441	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—sarcoma	3.08e-05	0.000441	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—sarcoma	3.05e-05	0.000437	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—sarcoma	3.01e-05	0.000431	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—sarcoma	2.97e-05	0.000426	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—sarcoma	2.93e-05	0.000421	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREB1—sarcoma	2.93e-05	0.00042	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—sarcoma	2.88e-05	0.000414	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—sarcoma	2.86e-05	0.00041	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—sarcoma	2.85e-05	0.000409	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—sarcoma	2.83e-05	0.000406	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—sarcoma	2.8e-05	0.000402	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—sarcoma	2.77e-05	0.000397	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—sarcoma	2.77e-05	0.000397	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FOXO1—sarcoma	2.74e-05	0.000394	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—sarcoma	2.74e-05	0.000394	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRB—sarcoma	2.74e-05	0.000393	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—sarcoma	2.73e-05	0.000392	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—sarcoma	2.73e-05	0.000392	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLCG1—sarcoma	2.7e-05	0.000387	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRA—sarcoma	2.7e-05	0.000387	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—sarcoma	2.65e-05	0.00038	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREB1—sarcoma	2.64e-05	0.000378	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREB1—sarcoma	2.6e-05	0.000373	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—sarcoma	2.56e-05	0.000367	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—sarcoma	2.52e-05	0.000362	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—sarcoma	2.49e-05	0.000358	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—sarcoma	2.49e-05	0.000357	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—sarcoma	2.49e-05	0.000357	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—sarcoma	2.46e-05	0.000353	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—sarcoma	2.42e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—sarcoma	2.38e-05	0.000342	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—sarcoma	2.35e-05	0.000337	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—sarcoma	2.29e-05	0.000329	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—sarcoma	2.27e-05	0.000326	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—sarcoma	2.25e-05	0.000323	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—sarcoma	2.24e-05	0.000322	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—sarcoma	2.18e-05	0.000313	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—sarcoma	2.17e-05	0.000311	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—sarcoma	2.15e-05	0.000309	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—sarcoma	2.12e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—sarcoma	2.11e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—sarcoma	2.11e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—sarcoma	2.09e-05	0.0003	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—sarcoma	2.09e-05	0.0003	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—sarcoma	2.09e-05	0.0003	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—sarcoma	2.03e-05	0.000291	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—sarcoma	2e-05	0.000287	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREB1—sarcoma	1.99e-05	0.000286	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—sarcoma	1.95e-05	0.00028	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—sarcoma	1.92e-05	0.000276	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—sarcoma	1.91e-05	0.000273	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—sarcoma	1.9e-05	0.000273	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—sarcoma	1.9e-05	0.000272	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—sarcoma	1.89e-05	0.000271	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—sarcoma	1.88e-05	0.00027	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—sarcoma	1.88e-05	0.00027	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—sarcoma	1.87e-05	0.000269	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—sarcoma	1.87e-05	0.000268	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—sarcoma	1.86e-05	0.000266	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—sarcoma	1.84e-05	0.000264	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—sarcoma	1.82e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—sarcoma	1.8e-05	0.000258	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—sarcoma	1.8e-05	0.000258	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—sarcoma	1.7e-05	0.000244	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—sarcoma	1.69e-05	0.000243	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—sarcoma	1.68e-05	0.000241	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—sarcoma	1.66e-05	0.000238	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—sarcoma	1.66e-05	0.000238	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—sarcoma	1.65e-05	0.000236	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—sarcoma	1.64e-05	0.000235	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—sarcoma	1.63e-05	0.000234	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—sarcoma	1.61e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—sarcoma	1.56e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—sarcoma	1.53e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—sarcoma	1.52e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—sarcoma	1.5e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—sarcoma	1.49e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—sarcoma	1.47e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—sarcoma	1.47e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—sarcoma	1.43e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—sarcoma	1.43e-05	0.000205	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—sarcoma	1.42e-05	0.000204	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—sarcoma	1.41e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—sarcoma	1.39e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—sarcoma	1.39e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—sarcoma	1.33e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—sarcoma	1.28e-05	0.000184	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—sarcoma	1.25e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—sarcoma	1.25e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—sarcoma	1.24e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—sarcoma	1.24e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—sarcoma	1.2e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—sarcoma	1.18e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—sarcoma	1.15e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—sarcoma	1.13e-05	0.000161	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—sarcoma	1.06e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—sarcoma	9.45e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—sarcoma	9.04e-06	0.00013	CbGpPWpGaD
